NPS Pharmaceuticals Inc (NPSP) financial statements (2021 and earlier)

Company profile

Business Address 550 HILLS DRIVE
BEDMINSTER, NJ 07921
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments164180101
Cash and cash equivalents665117
Short-term investments9912983
Receivables494130
Inventory, net of allowances, customer advances and progress billings3730
Inventory3730 
Prepaid expense56
Prepaid expense and other current assets6
Other current assets11
Total current assets:256259137
Noncurrent Assets
Property, plant and equipment644
Intangible assets, net (including goodwill)27299
Goodwill999
Intangible assets, net (excluding goodwill)1819 
Other noncurrent assets0 
Other undisclosed noncurrent assets000
Total noncurrent assets:333314
TOTAL ASSETS:290292151
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities423018
Accounts payable22114
Accrued liabilities19179
Interest and dividends payable124
Debt1096
Other undisclosed current liabilities3206
Total current liabilities:565830
Noncurrent Liabilities
Long-term debt and lease obligation90124170
Long-term debt, excluding current maturities90124170
Liabilities, other than long-term debt1057
Other liabilities1057
Total noncurrent liabilities:100129176
Total liabilities:156187206
Stockholders' equity
Stockholders' equity attributable to parent134105(55)
Common stock000
Additional paid in capital1,1671,127954
Accumulated other comprehensive income (loss)(2)00
Accumulated deficit(1,031)(1,023)(1,009)
Total stockholders' equity:134105(55)
TOTAL LIABILITIES AND EQUITY:290292151

Income statement (P&L) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Revenues224156131
Revenue, net224156131
Cost of revenue
(Cost of Goods and Services Sold)
(15)(4) 
Gross profit:209152131
Operating expenses(204)(153)(132)
Operating income (loss):5(1)(1)
Nonoperating expense(13)(12)(18)
Interest and debt expense(14)(12)(18)
Other undisclosed income from continuing operations before equity method investments, income taxes141218
Loss from continuing operations before income taxes:(8)(13)(19)
Income tax expense(1)(0) 
Net loss available to common stockholders, diluted:(9)(14)(19)

Comprehensive Income ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Net loss:(9)(14)(19)
Other comprehensive income (loss)(2)0 
Comprehensive loss:(11)(13)(19)
Other undisclosed comprehensive income, net of tax, attributable to parent  0
Comprehensive loss, net of tax, attributable to parent:(11)(13)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: